|
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
/PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II...
|
|
|
Bioheart Collaborating Researchers to Present At the Fifth International Conference on Cell Therapy for Cardio
SUNRISE, Fla., Jan.9, 2009 (GLOBE NEWSWIRE) -- Bioheart, Inc. (NasdaqCM:BHRT - News), a company developing core technologies aimed at serving the heart failure patient population, announced today that eight of its affiliated researchers...
|
|
|
Second Asia-Pacific Clinical Trials Congress, 2008
The second Asia Pacific Clinical Trials Congress 2008 (APCTC) was held on 21-22nd November 2008 at, Andheri, Mumbai.The event was organised by the Indian Drug Manufacturers' Association (IDMA) Medical Subcommittee. Daara B...
|
|
|
Despite Faster FDA Review New Drug Development Still Takes 8 Years, According To Tufts CSDD
Regulatory Affairs / Drug Approvals News Main Category: Regulatory Affairs / Drug Approvals Also Included In: Pharma Industry / Biotech Industry; Biology / Biochemistry; Clinical Trials / Drug Trials email to a friend...
|
|
|
India a hot destination for clinical trials
Related topics: Clinical evolution, Clinical Development, Phase I-II, Phase III-IV The proportion of global clinical trials conducted In India is expected to more than double between 2007 and 2012, according to market...
|
|
|
Clinical Trials in Practice: The Business of Drug Approval
Participating in clinical trials can be advantageous to both clinicians and their patients.ANDREW E. MATHIS, PhD, MEDICAL EDITOR As most retinal physicians are aware, no drug requiring a prescription or new medical device can be...
|
|
|
Poniard Pharmaceuticals, Inc. (PARD) to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal
SOUTH SAN FRANCISCO, Calif., Jan.7 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced that the Company will present data from two ongoing Phase...
|
|
|
Advaxis' Phase II Clinical Trial 'HOLD' Lifted
Advaxis Inc (OTCBB: ADXS), a biotechnology company, received permission from the U.Food and Drug Administration (FDA) to test its lead drug candidate, Lovaxin C, in patients with grade 2/3 cervical intraepithelial neoplasia (CIN). With...
|
|
|
Clinical Data, Inc. Reports Advances in Two Late-Stage Therapeutic Programs
Vilazodone and Stedivaze Phase III Trials on Track to Meet Key 2009 Milestones We continue to make significant progress in both of our late-stage drug development programs and believe this reflects the knowledge, expertise and...
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate FREMONT, Calif., Jan.8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company...
|
|
|
Quark Pharmaceuticals Inc. (QURK) Announces Dosing of the First Patient in Phase I/II Clinical Trial for Syste
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate FREMONT, Calif., Jan.8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company...
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate FREMONT, Calif., Jan.8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company...
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate FREMONT, Calif., Jan.8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company...
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate FREMONT, Calif., Jan.8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company...
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate FREMONT, Calif., Jan.8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company...
|
|
|
Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
- Picoplatin Phase 2 Colorectal and Prostate Cancer Data to be presented at ASCO GI and ASCO GU Symposia; SPEAR Small Cell Lung Cancer Trial on Track to Complete Enrollment - Related: SOUTH SAN FRANCISCO, Jan.8 /PRNewswire-FirstCall...
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate FREMONT, Calif., Jan.8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company...
|
|
|
Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
- Picoplatin Phase 2 Colorectal and Prostate Cancer Data to be presented at ASCO GI and ASCO GU Symposia; SPEAR Small Cell Lung Cancer Trial on Track to Complete Enrollment - SOUTH SAN FRANCISCO, January 08, 2009 /PRNewswire-FirstCall/...
|
|
|
Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine
- Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced positive results from a Phase 1 clinical trial of its lead compound,...
|
|
|
Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine
Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced positive results from a Phase 1 clinical trial of its lead compound, JVRS...
|
|
|
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Deli
/PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II...
|
|
|
Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine
BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced positive results from a Phase 1 clinical ...
|
|
|
Osteotech Initiates Pivotal Clinical Trial For DuraTech(TM) BioRegeneration Matrix
Osteotech, Inc.(Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced that it has initiated a pivotal clinical trial for its DuraTech(TM) BioRegeneration Matrix. The first five...
|
|
|
CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Ca
CureVacs RNActive mRNA vaccine CV9103 to treat prostate cancer is approved for clinical studies in the US TUEBINGEN, Germany, January 8, 2009 - CureVac GmbH announced that it has received approval for its Investigational New Drug (IND)...
|
|
|
Unibioscreen Announces Progress Of Phase I Clinical Trial For UNBS1450 In Europe In Cancer Patients With Advan
Unibioscreen S.A., the Brussels-based specialist oncology company, is pleased to announce that the clinical testing of its second experimental anti-cancer drug, UNBS1450, which is being administered in cancer patients since October 2008, is...
|
